This is unpublished

APOC3-mediated dyslipidemia in kidney disease and atherosclerosis in diabetes

Study image of cell
Active Studies
CKD
Diabetes
Laboratory Studies
Pinned
Principal Investigator
Jenny Kanter
Funding Agency
NIDDK
Status
Active
Laboratory Study

Investigator

Jenny Kanter

 

 

 

Jenny Kanter, PhD
 

WHAT IS the Study?

THE APOC3-mediated dyslipidemia in kidney disease and atherosclerosis in diabetes Study

Apolipoprotein C3 (APOC3) is a protein produced in the liver that regulates triglyceride-rich lipoprotein (TRL) metabolism. It is often elevated in diabetes and people with kidney disease. It is a risk factor for cardiovascular disease in people with type 1 diabetes.

In this study, we want to understand how APOC3 and the lipids it regulates might contribute to the progression of diabetic kidney disease and atherosclerosis.

Kanter Lab study image

WHAT ARE THE GOALS OF THE STUDY?

The goals of the study are to address the following questions:

  • Do plasma levels of APOC3 predict reduced kidney function in people with diabetes?
  • If we reduced levels of APOC3 in a mouse model of diabetic kidney disease (DKD), does it reduce markers of DKD?
  • If we reduced levels of APOC3 in a mouse model of diabetes-accelerated atherosclerosis, does it reduce atherosclerosis?
  • What are the mechanisms by which reducing circulating TRLs prevents DKD?

WHO CAN JOIN THE STUDY?

We are not recruiting patients. This is a laboratory study.

 

WHO DO I CONTACT FOR MORE INFORMATION?

Principal Investigator

Jenny Kanter
Kanter Lab
jenka@uw.edu

PUBLICATIONS

Elevated Apolipoprotein C3 Augments Diabetic Kidney Disease and Associated Atherosclerosis in Type 2 Diabetes